Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Market Analysis & Valuation

UpdatedJan 21, 2026
DataAggregated Company Financials
Companies208
  • 7D-1.0%
  • 3M5.3%
  • 1Y7.4%
  • YTD-0.02%

In the last week, the market has been flat, with a notable exception in the Consumer Discretionary sector dropping 9.1%. More promisingly, the market is up 9.1% over the past year. Looking forward, earnings are forecast to grow by 11% annually.

Market Valuation and Performance

Has the Swiss Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 21 Jan 2026CHF 2.0tCHF 795.6bCHF 114.6b20.3x17.4x2.5x
Fri, 19 Dec 2025CHF 2.0tCHF 797.6bCHF 114.3b20.1x17.2x2.5x
Sun, 16 Nov 2025CHF 1.9tCHF 799.4bCHF 113.8b19.5x16.7x2.4x
Tue, 14 Oct 2025CHF 1.9tCHF 776.0bCHF 90.4b19.5x20.9x2.4x
Thu, 11 Sep 2025CHF 1.9tCHF 775.0bCHF 90.1b19.5x20.7x2.4x
Sat, 09 Aug 2025CHF 1.8tCHF 776.2bCHF 89.9b20.7x20.3x2.4x
Mon, 07 Jul 2025CHF 1.8tCHF 784.4bCHF 106.7b20.2x16.9x2.3x
Wed, 04 Jun 2025CHF 1.8tCHF 786.3bCHF 106.5b20.2x17.2x2.3x
Fri, 02 May 2025CHF 1.8tCHF 838.2bCHF 157.9b19.4x11.3x2.1x
Sun, 30 Mar 2025CHF 1.9tCHF 849.8bCHF 158.9b20x11.8x2.2x
Tue, 25 Feb 2025CHF 1.9tCHF 811.8bCHF 117.3b21.2x16.3x2.4x
Thu, 23 Jan 2025CHF 1.8tCHF 817.8bCHF 117.8b21.3x15.4x2.2x
Sat, 21 Dec 2024CHF 1.7tCHF 812.7bCHF 117.3b20.6x14.6x2.1x
Mon, 18 Nov 2024CHF 1.7tCHF 811.6bCHF 117.2b19.8x14.8x2.1x
Wed, 16 Oct 2024CHF 1.8tCHF 805.2bCHF 114.2b21.1x16x2.3x
Fri, 13 Sep 2024CHF 1.8tCHF 803.3bCHF 114.0b20.9x15.7x2.2x
Sun, 11 Aug 2024CHF 1.8tCHF 802.5bCHF 136.5b20.9x13.1x2.2x
Tue, 09 Jul 2024CHF 1.8tCHF 801.6bCHF 126.0b21.4x14.4x2.3x
Thu, 06 Jun 2024CHF 1.8tCHF 800.5bCHF 125.5b22.1x14.5x2.3x
Sat, 04 May 2024CHF 1.7tCHF 797.7bCHF 125.2b21.4x13.7x2.1x
Mon, 01 Apr 2024CHF 1.8tCHF 766.5bCHF 96.9b21.9x18.4x2.3x
Wed, 28 Feb 2024CHF 1.7tCHF 789.2bCHF 110.7b19.9x15.6x2.2x
Fri, 26 Jan 2024CHF 1.7tCHF 765.8bCHF 110.4b17.7x15.2x2.2x
Sun, 24 Dec 2023CHF 1.7tCHF 763.3bCHF 109.8b18.4x15.3x2.2x
Tue, 21 Nov 2023CHF 1.6tCHF 772.3bCHF 111.4b18x14.6x2.1x
Thu, 19 Oct 2023CHF 1.6tCHF 760.9bCHF 100.6b17.9x15.9x2.1x
Sat, 16 Sep 2023CHF 1.7tCHF 750.8bCHF 99.4b18.8x16.8x2.2x
Mon, 14 Aug 2023CHF 1.7tCHF 745.8bCHF 75.2b18.2x22.3x2.3x
Wed, 12 Jul 2023CHF 1.7tCHF 753.3bCHF 76.5b18.8x22x2.2x
Fri, 09 Jun 2023CHF 1.7tCHF 786.4bCHF 82.5b19x21x2.2x
Sun, 07 May 2023CHF 1.8tCHF 785.8bCHF 81.4b19.4x21.9x2.3x
Tue, 04 Apr 2023CHF 1.7tCHF 780.4bCHF 69.3b19.4x25x2.2x
Thu, 02 Mar 2023CHF 1.7tCHF 785.3bCHF 71.0b19.4x24.1x2.2x
Sat, 28 Jan 2023CHF 1.8tCHF 787.0bCHF 94.4b17.9x18.8x2.3x
Price to Earnings Ratio

18.8x


Total Market Cap: CHF 1.8tTotal Earnings: CHF 94.4bTotal Revenue: CHF 787.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Market Price to Earnings3Y Average 17.4x202420252026
Current Market PE
  • Investors are relatively neutral on the Swiss market at the moment, indicating that they expect earnings will grow in line with historical growth rates.
  • The market is trading close to its 3-year average PE ratio of 17.4x.
Past Earnings Growth
  • The earnings for Swiss listed companies have grown 6.8% per year over the last three years, while revenues have remained steady.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Sector Trends

Which sectors have driven the changes within the Swiss Market?

CH Market-0.99%
Real Estate1.97%
Telecom1.05%
Healthcare0.39%
Financials-0.36%
Industrials-0.56%
Consumer Staples-1.60%
Materials-2.03%
Tech-2.89%
Utilities-9.22%
Consumer Discretionary-9.97%
Sector PE
  • Investors favour the Tech sector the most for future growth, which is trading above its 3-year average PE ratio of 30.0x.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 20.6% which is higher than its past year's earnings decline of 1.2% per year.
  • The Financials sector is the least preferred by investors for future growth, which is trading below its 3-year average of 8.6x.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 21% over the next 5 years.
  • This is better than its past earnings decline of 1.2% per year.
  • In contrast, the Real Estate sector is expected to see its earnings decline by 7.7% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
ROG Roche HoldingCHF 346.001.5%
+CHF 4.3b		28.1%PE31.2xHealthcare
VACN VAT GroupCHF 505.0014.6%
+CHF 1.9b		47.1%PE67.8xIndustrials
PGHN Partners Group HoldingCHF 1.07k5.0%
+CHF 1.3b		-21.1%PE23.1xFinancials
NOVN NovartisCHF 114.260.5%
+CHF 1.2b		27.9%PE19.3xHealthcare
SDZ Sandoz GroupCHF 61.263.4%
+CHF 870.0m		47.1%PE147.3xHealthcare
See more

Market Insights

Header cover image
Why Didn’t Oil React to Venezuela? 🇻🇪
Stella Ong avatar
Stella Ong
|
|
Maduro is out, the US stepped in… and oil markets barely reacted? Let’s look at why.
Continue reading
Which Markets Will Sink or Swim in 2026? 🌍
Last Week

Which Markets Will Sink or Swim in 2026? 🌍

Latest News

UBSG
CHF 37.02
UBS Group
7D
-2.5%
1Y
17.4%

UBSG: Execution And Legal Risks Will Challenge Sustainability Of Current Valuation

Analysts have lifted their price targets on UBS Group into a CHF 30 to CHF 43 range, citing updated assumptions for slightly higher revenue growth, a modestly lower profit margin and a small increase in the future P/E multiple. Analyst Commentary Recent Street research on UBS Group shows a wide range of views, with price targets stretching from CHF 30 to CHF 43 and ratings running from Underweight to Overweight.
GALD
CHF 153.80
Galderma Group
7D
-3.2%
1Y
40.7%

GALD: Raised Growth Outlook And L’Oréal Stake Increase Will Support Re Rating

Analysts have raised their blended price target range for Galderma Group to approximately CHF 195 to CHF 200 from about CHF 140 to CHF 165, citing updated fair value estimates, revised assumptions for revenue growth and profit margins, as well as a higher projected P/E multiple. Analyst Commentary Recent Street research points to a more constructive stance on Galderma Group, with several bullish analysts lifting their price targets into the CHF 140 to CHF 195 range.
GEBN
CHF 601.60
Geberit
7D
-5.1%
1Y
19.0%

GEBN: Raised Guidance And Modestly Higher Assumptions Will Support Long Term Upside

Narrative Update on Geberit Geberit's analyst price target has edged up to CHF 528 from CHF 523. This reflects analysts’ updated assumptions on discount rates, revenue growth, profit margins and future P/E multiples.
NOVN
CHF 114.26
Novartis
7D
0.5%
1Y
27.9%
CFR
CHF 156.05
Compagnie Financière Richemont
7D
-11.1%
1Y
-6.0%
VACN
CHF 505.00
VAT Group
7D
14.6%
1Y
47.1%
SDZ
CHF 61.26
Sandoz Group
7D
3.4%
1Y
47.1%
SCMN
CHF 599.00
Swisscom
7D
2.4%
1Y
16.3%

Swisscom AG's (VTX:SCMN) Share Price Could Signal Some Risk

Jan 14
Swisscom AG's (VTX:SCMN) Share Price Could Signal Some Risk
EMSN
CHF 597.00
EMS-CHEMIE HOLDING
7D
4.9%
1Y
-6.9%

Estimating The Fair Value Of EMS-CHEMIE HOLDING AG (VTX:EMSN)

Jan 14
Estimating The Fair Value Of EMS-CHEMIE HOLDING AG (VTX:EMSN)
NESN
CHF 73.94
Nestlé
7D
-1.7%
1Y
-1.1%

NESN: Portfolio Review And 2026 Execution Reset Are Expected To Unlock Upside

Analysts have trimmed their overall price expectations for Nestlé slightly, with our updated fair value estimate easing from CHF 88.15 to about CHF 87.69, as they factor in a mix of lower revenue growth assumptions, a marginally higher profit margin outlook, and a modestly lower future P/E. This is consistent with recent Street price target resets between CHF 76 and CHF 92.
AMRZ
CHF 42.03
Amrize
7D
-6.2%
1Y
n/a

Is Amrize (VTX:AMRZ) Using Too Much Debt?

Jan 11
Is Amrize (VTX:AMRZ) Using Too Much Debt?
BEAN
CHF 879.00
BELIMO Holding
7D
6.2%
1Y
29.6%

BEAN: Tariff Cost Pressures Will Test But Not Break Long Term Thesis

Analysts have trimmed their fair value estimate for BELIMO Holding from CHF 1,100 to CHF 1,000 as they factor in a slightly higher discount rate, more moderate revenue growth assumptions, and tariff related pressure on material costs and gross profits, even while assuming a higher profit margin and a lower future P/E multiple. Analyst Commentary Some bullish analysts remain constructive on BELIMO Holding even as they trim their fair value assumptions.
ROG
CHF 346.00
Roche Holding
7D
1.5%
1Y
28.1%

ROG: 2026 Clinical Readouts Will Shape Sentiment On Pipeline Execution

Analysts have lifted their fair value estimate for Roche Holding from CHF 400.07 to CHF 427.00, citing recent upgrades, clinical readouts and what they see as an undemanding valuation, which they believe is supported by 2026 clinical catalysts and ongoing program progress. Analyst Commentary Recent Street research around Roche highlights a cluster of positive opinions that center on clinical execution, program progress and what some see as a valuation that does not fully reflect these factors.
PGHN
CHF 1,065.00
Partners Group Holding
7D
5.0%
1Y
-21.1%

PGHN: Hospitality Real Estate Expansion Will Support Future Upside Potential

Analysts held their fair value estimate for Partners Group Holding at CHF 1,400.00. The updated target reflects slightly adjusted assumptions for discount rate, revenue growth, profit margins and a higher future P/E multiple, which together refine rather than overhaul their previous view.
ABBN
CHF 59.90
ABB
7D
-1.6%
1Y
16.0%

ABBN: Higher Fair Value View Will Rely On Data Center Expansion

Analysts have raised their fair value estimate for ABB from about $63.81 to roughly $72.70, citing updated assumptions related to revenue growth, discount rates, profit margins and future P/E levels. What's in the News Blackstone is reported to be close to a roughly US$4b deal for MacLean Power Systems after ABB chose not to increase its competing offer, according to people familiar with the matter (Bloomberg / M&A talks).
LONN
CHF 543.60
Lonza Group
7D
-3.0%
1Y
-4.7%

Is There Now An Opportunity In Lonza Group AG (VTX:LONN)?

Dec 22
Is There Now An Opportunity In Lonza Group AG (VTX:LONN)?